38 results about "Rhinovirus infection" patented technology

The disclosed invention provides compositions and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially humans, using a (2′R)-2′-deoxy-2′-fluoro-2′-C-methyl nucleosides, or a pharmaceutically acceptable salt or prodrug thereof.

Medicinal use The disclosure relates to compounds of formula (I) for use in the treatment or prophylaxis of respiratory syncitial virus (RSV) infection in particular viral exacerbation of a respiratory disorder such as bronchitis, asthma, COPD and / or cystic fibrosis, methods of treating or preventing RSV infection employing said compounds or pharmaceutical composition comprising the same.

The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Picornaviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of Enterovirus and / or Rhinovirus infection in a mammal. The antisense antiviral compounds are substantially uncharged, morpholino oligonucleotides have a sequence of 12-40 subunits, including at least 12 subunits having a targeting sequence that is complementary to a region associated with viral RNA sequences within a 32 nucleotide region of the viral 5′ untranslated region identified by SEQ ID NO:7.

The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Picornaviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of Enterovirus and / or Rhinovirus infection in a mammal. The antisense antiviral compounds are substantially uncharged, including partially positively charged, morpholino oligonucleotides have a sequence of 12-40 subunits, including at least 12 subunits having a targeting sequence that is complementary to a region associated with viral RNA sequences within a 32 nucleotide region of the viral 5′ untranslated region identified by SEQ ID NO:4.

The invention provides a method for evaluating the activity of an agent for treating rhinovirus infection or a symptom thereof, a method of detecting or monitoring rhinovirus infection, and a method of treating rhinovirus infection or a symptom thereof. Various embodiments comprise measuring expression of (i) one or more genes selected from the group consisting of CRY2, B3GAT3, C10ORF95, and BATF3, and (ii) one or more genes selected from the group consisting of RNFT2, BTG4, PSD3, CAPN9, SULT1E1, HEY1, LRRC36, RAB3B, ALDH3B1, FAM134B, FAS, PLSCR1, CLEC2B, HAS2, MX1, SP110, GBP1, IFIT3, IFIT1, CXCL9, CXCL10, and CXCL11, from at least one biological sample to produce a gene expression profile, and comparing the gene expression profile to a reference gene expression profile. Systems, computer readable media, compositions, and methods for maintaining or improving respiratory health also are provided.

The immunoadhesions of the present invention are useful in treating rhinovirus infections. The immunoadhesions contain a chimeric ICAM molecule and may optionally also contain J chain and secretory compounds. The chimeric ICAM molecule is a fusion protein that has a rhinovirus receptor protein linked to an immunoglobulin protein. This invention also includes the greatly increased and improved method of producing immunoadhesions in plants. Each of the components of an immunoadhesin is produced in a plant cell and thereby assembles within the plant cell. This method of producing the immunoadhesions of the present invention results in the efficient and economic production of these molecules. The present invention also contemplates the production of immunoadhesions in a variety of eukaryotic cells including plants and mammalian cells. The immunoadhesions of the present invention are useful as a therapeutic against the common cold in humans which is caused by rhinoviruses.

The present invention provides the use of carrageenan or mixtures thereof for the manufacture of an antiviral pharmaceutical composition for the treatment of rhinovirus infections.

The present invention provides methods for identifying genes, expression regulators, receptors, protein product receptors, and proteins that may regulate rhinovirus infections. The genes identified may be used as markers for disease onset and progression and to measure efficacy of a therapeutic. The present invention also provides methods to screen agents that are capable of regulating rhinovirus infection. The present invention also provides methods of identifying therapeutic compounds that may treat various disorders by regulating the expression and activity of genes, expression regulators, receptors, protein product receptors, and proteins identified.

The invention relates to methods and compositions for preventing or treating human rhinovirus infection.

The invention provides a method for rapidly detecting HRV typing and EV by single-tube multiplex-RT-PCR. The method comprises the following steps: a) collecting a sample; b) extracting nucleic acid from the sample; c) adding the extracted nucleic acid to a premixed RT-PCR reagent; d) running an RT-PCR amplification program; and e) performing fragment analysis on the obtained RT-PCR amplification product, wherein the premixed RT-PCR reagent contains a primer specifically for HRV typing and a primer specifically for EV. The method has the advantages of simplicity in operation, short time and high flux, so a result can be obtained in 4 h at the soonest, and the method is suitable for clinic detection and scientific researches. The HRV virus typing result detected by the method can be used forguiding clinicians to medicate, and also can be used for the pathological study of rhinovirus infection.

A method for manufacturing an antiviral pharmaceutical composition for the prophylaxis or treatment of a rhinovirus infection that includes the utilization of iota-, kappa- or lambda-carrageenan or mixtures thereof.

The invention relates to a method for producing drug that treats virus infection of respiratory tract, wherein it uses Arbidol Hydrochloride as 6-bromine-4-(dimethylamino)-5-hydroxyl group-1-methyl-2-(benzene sulfenyl)-1H-indole-3-glycolate-hydrates. The invention can reduce the mouse dead rate affected by virus B3, B5, adenovirus, etc, and improve antibody level, with wide application.

The alpha-interferon has been used mainly in treating chronic viral infection. The present invention uses coronavirus or rhinovirus infected human cervical cancer cell as estimation model in observing the inhibition effect of alpha-interferon on common virus causing respiratory system infection. The results show that alpha-interferon may be used in preventing and treating coronavirus and rhinovirus caused diseases, including SARS. The integrated interferon, its mutant and interferon alpha-1b have even high inhibiting effect on new SARS virus.

Use of interferon-beta (IFN-β) and / or IFN-λ for treating rhinovirus (RV) infection in elderly people, particularly elderly people who are, or have been long-term smokers, especially those who have a clinical history of recurrent RV infections, and may have other medical conditions, such as cardiac or circulation problems, and who are liable to suffer severe complications / high mortality from poor innate ability to fight such a viral infection.

The invention relates to methods and compositions for preventing or treating human rhinovirus infection.

Nitric oxide generating compounds or compounds which induce in situ synthesis of nitric oxide can be used to inhibit rhinovirus infection. Nitric oxide has the ability to inhibit both viral replication as well as the synthesis of cytokines, in particular the proinflammatory cytokines. Thus the symptoms of rhinovirus infections can be ameliorated by treatments to increase nitric oxide in the respiratory tract.

The invention relates to methods and compositions for preventing or treating human rhinovirus infection.

The present invention relates to methods, compositions and kits for the treatment or prevention of respiratory conditions. In particular, the methods, compositions and kits are particularly useful, but not limited to, the prevention and / or treatment of rhinovirus infection and the prevention and / or treatment of asthma exacerbation. The invention provides a method inhibiting a rhinovirus infection in a subject comprising administering a composition consisting of a compound comprising a TLR2 agonist and a pharmaceutically acceptable carrier.

The invention provides a method for evaluating the activity of an agent for treating rhinovirus infection or a symptom thereof, a method of detecting or monitoring rhinovirus infection, and a method of treating rhinovirus infection or a symptom thereof. Various embodiments comprise measuring expression of (i) one or more genes selected from the group consisting of CRY2, B3GAT3, C10ORF95, and BATF3, and (ii) one or more genes selected from the group consisting of RNFT2, BTG4, PSD3, CAPN9, SULT1E1, HEY1, LRRC36, RAB3B, ALDH3B1, FAM134B, FAS, PLSCR1, CLEC2B, HAS2, MX1, SP110, GBP1, IFIT3, IFIT1, CXCL9, CXCL10, and CXCL11, from at least one biological sample to produce a gene expression profile, and comparing the gene expression profile to a reference gene expression profile. Systems, computer readable media, compositions, and methods for maintaining or improving respiratory health also are provided.

The invention relates to an electronic detection device and kit for influenza viruses and rhinoviruses and relates to the field of respiratory virus detection. The electronic detection device comprises a photoelectric detection module, a data processing module and colloidal gold detection test paper, wherein the colloidal gold test paper comprises a bottom lining, a nitrocellulose film, a gold padand a sample pad, the nitrocellulose film is fixed on the bottom lining, the gold pad is arranged between the nitrocellulose film and the sample pad, one side of the gold pad is partially overlappedwith the nitrocellulose film, the other side of the gold pad is partially overlapped with the sample pad, the nitrocellulose film coats a detection line and a quality control line close to one side ofthe gold pad, the detection line comprises a plurality of virus detection lines, the gold pad is made of mixture of multiple gold-labeled virus monoclonal antibodies, the photoelectric detection module is used for detecting color changes of the quality control line and the detection line, and the data processing module is used for judging whether influenza virus or rhinovirus infection exists ornot according to the color change detected by the photoelectric detection module. The electronic detection device is advantaged in that purposes of rapidness, convenient operation and low-cost detection can be achieved.

Methods, kits, and compositions are disclosed for vaccinating a human or animal against human rhinovirus infection. Also provided are methods of using a cotton rat model for identifying and testing vaccines and therapeutic agents that prevent or ameliorate human rhinovirus infection.

The present invention provides a kind of single-tube multiple RT-PCR rapid detection method for HRV typing and EV, comprising the steps of: a) collecting samples; b) extracting nucleic acids from the samples; c) adding the extracted nucleic acids to In the premixed RT-PCR reagent; d) run the RT-PCR amplification program; e) fragment analysis is carried out to the RT-PCR amplified product; wherein, the premixed RT-PCR reagent comprises specific primers for HRV typing and primers specific for EVs. The method is simple in operation, short in time, can produce results within 4 hours at the fastest, and has high throughput and is suitable for clinical testing and scientific research. The HRV virus typing result detected by the method can guide clinicians to use medicine, and can also be used for pathological research of rhinovirus infection.

The present invention provides ester derivatives of hydroxybenzoic acid for use in the treatment or prevention of a rhinovirus infection in a mammal wherein R represents a C1-10 alkyl group, X1, X2, X3, X4 and X5 independently represent —H or —OH and wherein at least one of X1, X2, X3, X4 and X5 is —OH.

The present invention is directed to the use of anti-malarial compound for the treatment and prophylaxis of infections by adenovirus or rhinovirus.

The invention discloses Zukamu granules. The Zukamu granules are prepared from rhizome kaempferiae, nymphaea tetragona, mint, jujubes, chamomile, cordia dichotoma fruits, liquorice, hollyhock seeds, rheum officinale and pericarpium papaveris. The Zukamu granules are used for resisting coxsakievirus and / or rhinovirus infection. The Zukamu granules can effectively inhibit activity of coxsakievirus and rhinovirus, regulate abnormal constitution, clear heat, promote sweating and open orifices and is used for treating cold coughs, fever adiaphoresis, sore throat and nasal congestion.

The present invention provides a pharmaceutical composition for use in prevention or treatment of a human rhinovirus (HRV) infection. The composition comprises an aldohexose, wherein the hydroxyl group at carbon 2 of the aldohexose is replaced by any one of H, F, Cl, Br, I, SH, Me, OMe and SMe, such as a 2-deoxy-glucose. Furthermore, a dispenser for intranasal administration, such as a nasal spray or nose drop applicator containing said pharmaceutical composition is provided. In addition, an inhalation device, such as a metered-dose inhaler, a dry-powder inhaler or a nebuliser, comprising said composition is provided.